Monte Rosa Therapeutics(GLUE)
Focus: Monte Rosa is an early-stage oncology-focused biotech developing small-molecule protein degradation modulators, recently gone public on NASDAQ (ticker: GLUE). The company operates with an R&D-first strategy in a capital-intensive therapeutic area with no approved products yet.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
16+4 this month
Stable — net +4 jobs in 30d
6 added, 2 removed. Backfill posture.
Should You Work at Monte Rosa Therapeutics?
AI assessmentSuitable for scientists and clinicians prioritizing discovery-stage impact and equity upside over near-term stability, but unsuitable for those seeking revenue visibility or near-term cash-out scenarios.
Why Work Here
- Exposure to cutting-edge protein degradation science—a validated oncology modality with significant patent protection and clinical validation runway
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Pipeline & Clinical Trials
MRT-6160
Healthy VolunteersClinical Trials (1)
NCT06597799First-in-human Study of MRT-6160 in Healthy Subjects
Phase 1Help build intelligence for Monte Rosa Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.